This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatmenteligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19symptom. This study will look at the change in Post Covid Conditions measured by thenumber of outpatients, Emergency department, urgent care and inpatient visits before andafter COVID-19 between those who did and did not receive Paxlovid. In addition, changesin frailty post-acute infection will be evaluated, in a separate analysis. It ishypothesized that individuals with COVID-19 who received Paxlovid will have a smallerpost-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e.,cardiopulmonary) in comparison to patients with COVID-19 who did not receive Paxlovid.
Not Provided
Drug: nirmatrelvir-ritonavir
Paxlovid standard of treatment care
Other Name: Paxlovid
Inclusion Criteria:
- Developed at least one COVID-19 symptom between Apr 1, 2022 through Dec 31, 2023
- A positive lab-confirmed polymerase chain reaction (PCR) SARS-COV-2 test 5 days
after symptom onset (primary analysis).
- Continuous enrollment in KPSC health plans for at least 1 year (allowing for a
31-day gap to account for potential delays in membership renewal) before the date of
symptom onset
- Active membership in KPSC health plans for at least 31 days after the date of
symptom onset
- Eligible for nirmatrelvir-ritonavir defined by age and CDC-defined risk factors for
severe COVID-19
Exclusion Criteria:
- Individuals on another medication that is contraindicated for treatment with
nirmatrelvir-ritonavir defined as having any prescription drug claim in the 90 days
prior to COVID-19 symptom onset
- Receipt of any COVID-19 antiviral (molnupiravir, remdesivir, nirmatrelvir/ritonavir)
or monoclonal antibody treatment (bamlanivimab, bebtelovimab, casirivimab/imdevimab,
cilgavimab/tixagevimab, otrovimab,) <180 days prior to COVID-19 symptom onset
- Any positive SARS-CoV-2 test, including self-reported tests, <180 days prior to
COVID-19 symptom onset.
Pfizer New York
New York 5128581, New York 5128638, United States
Pfizer CT.gov Call Center, Study Director
Pfizer